Experimental group: anlotinib(d1-14, d22-36), followed by 21 days period, 2 weeks medication, 1 week maintenance therapy.
. Group II: 10 mg po qd, Group III: 12 mg po qd;
Combined chemotherapy:
Cisplatin + etoposide Or PC: carboplatin AUC2, paclitaxel 45-50 mg 2 per week; Cisplatin + cultured beauty (non squamous cell carcinoma). Synchrotron radiation: radiotherapy combined with radiotherapy (3D-CRT or IMRT) (60-66Gy / day).
The curative effect was evaluated after 6 weeks of simultaneous radiotherapy and chemotherapy combined with alotinib, and then the efficacy of alotinib or chemotherapy was maintained until PD.

Patients With Non-small Cell Lung Cancer

Simultaneous chemoradiotherapy for An Luo

The second affiliated Hospital of Xi'an Jiaotong University

Study of Anlotinib Plus Chemoradiotherapy in Patients With Locally Advanced NSCLC

Phase I / II Clinical Study on the Safety and Preliminary Efficacy of Anlotinib Hydrochloride Combined With Platinum-containing Simultaneous Radiotherapy in the Treatment of Locally Advanced Non-small Cell Lung Cancer

complete response(CR)+partial response(PR) according to RECIST 1.1

overall survival is defined as the time from randomization to death from any cause

progression-free survival is defined as the time from enrollment to the date of first document disease progression or death from any cause

Second Affiliated Hospital of Xi'an Jiaotong University

Tang-Du Hospital

Xijing Hospital

First Affiliated Hospital Xi'an Jiaotong University

Shaanxi Provincial Cancer Hospital

Shaanxi Provincial People's Hospital

Experimental group: anlotinib (D1-14, d22-36, followed by 21 days cycle, taking medicine for 2 weeks, stopping for 1 week).
Group 1: 8mg po qd, Group 2: 10mg po qd, Group 3: 12mg po qd;
Combined chemotherapy:
Cisplatin + etoposide or PC: carboplatin AUC2, paclitaxel 45-50 mg 2 per week; Cisplatin + pemetrexed (non-squamous cell carcinoma). Simultaneous radiotherapy: 3D-CRT or IMRT external radiotherapy (60-66 Gy, 2.0 Gy / day).
The curative effect was evaluated after 6 weeks of simultaneous radiotherapy and chemotherapy combined with alotinib, and then the efficacy of alotinib or chemotherapy was maintained until PD.

Patients in the group A are orally administered eicosapentaenoic acid ethyl ester.

Patients in the group B (control) are not administered eicosapentaenoic acid ethyl ester.

Subarachnoid Hemorrhage

Cerebral Vasospasm

Orally administered 900 mg eicosapentaenoic acid ethyl ester three times a day (2700 mg ⁄ day) from the surgery next day to 30 days after the onset of SAH.

Eicosapentaenoic acid ethyl ester

Ootemachi Hospital

Nakamura Memorial Hospital

Iwate Medical University

Tohoku University

Yamaguchi University Hospital

Eicosapentaenoic Acid Cerebral Vasospasm Therapy Study

Eicosapentaenoic Acid Cerebral Vasospasm Therapy Study (EVAS): Effect of Eicosapentaenoic Acid on Cerebral Vasospasm Following Subarachnoid Hemorrhage

Eicosapentaenoic acid Cerebral Vasospasm Therapy Study (EVAS) Group

30,000 units of erythropoietin beta in one vial; 3 vials as one set per patient

Aneurysmal Subarachnoid Hemorrhage

30,000 units in 6 mL of 0.9% saline IV for 15 minutes every other day for 3 doses within 72 hours after aneurysmal subarachnoid hemorrhage

erythropoietin beta

Department of Neurosurgery, Addenbrooke's Hospital

Erythropoietin Therapy for Subarachnoid Hemorrhage

Effects of Systemic Erythropoietin Therapy on Cerebral Autoregulation and Incidence of Delayed Ischemic Deficits in Patients With Aneurysmal Subarachnoid Hemorrhage

subarachnoid hemorrhage/tyrosine

Study of Anlotinib Plus Chemoradiotherapy in Patients With Locally Advanced NSCLC

Eicosapentaenoic Acid Cerebral Vasospasm Therapy Study

Erythropoietin Therapy for Subarachnoid Hemorrhage

Il database di erbe medicinali più completo supportato dalla scienza